Project Grant R43EY037607
Award Date
7/1/25
Completion Date
6/30/26
Dollars Obligated
$307K
Federal Agency
National Eye Institute
Awardee
Piximune. Inc. (MCP3BLUNWGQ3)
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This $380,000 Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), supports research to investigate the role of interphotoreceptor matrix proteoglycans in retinal homeostasis and retinitis pigmentosa. The project aims to: 1) Explore how the proteoglycans IMPG1 and IMPG2 facilitate nutrient exchange between the retina and retinal pigment epithelium, and how mutations in these molecules lead to adult-onset retinitis pigmentosa; 2) Determine...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), aims to develop a mutation-independent therapy for retinal degenerations caused by mutations in the PRPH2 gene. The $431,750 award will fund research to determine the efficacy of reducing rhodopsin levels, a key component of photoreceptors, as a potential treatment approach across multiple mouse models expressing different PRPH2 mutations. The research will evaluate...
This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), is funding the development of OPGX-RHO, a single-vector gene therapy for the treatment of autosomal-dominant retinitis pigmentosa (ADRP). The $882,971 award supports two key objectives: 1) completing chemistry, manufacturing, and controls for a clinical-grade batch of OPGX-RHO, including stability studies and device compatibility testing, and 2) conducting efficacy and...
The National Eye Institute (NEI) awarded Revopsis Therapeutics, Inc. a $933,533 Project Grant under the Vision Research program (CFDA 93.867) to advance the development of their first-in-class RO-104 trispecific surrobody treatment for retinal diseases. RO-104 simultaneously targets three key angiogenic factors - VEGF-A, VEGF-C, and Ang-2 - that contribute to vision loss in conditions like age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. The award will fund...
The National Eye Institute (NEI), under the Department of Health and Human Services, awarded a $440,806 Project Grant (CFDA 93.867 - Vision Research) to The Research Foundation for the State University of New York (RF SUNY) to study the role of the molecular chaperone p58IPK in retinal neurons under diabetic conditions. The goal is to define the in vivo function of p58IPK in regulating protein and lipid homeostasis through the integrated stress response and lipid glycosylation pathways, and to...
The U.S. National Eye Institute (NEI) awarded a $184,117 Project Grant (CFDA 93.867 - Vision Research) to Oakland University to determine the role of G-coupled protein receptors GPR31 and GPR39 in the pathogenesis of diabetic retinopathy. The project aims to investigate the affinities and substrate specificities of GPR31 and GPR39 for 12- and 15-HETE metabolites in retinal endothelial cells and Müller cells under normal and hyperglycemic conditions. It will also examine the effects of GPR31 or...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), aims to develop universally immune-compatible induced pluripotent stem cells (iPSCs) for regenerative therapies to treat various eye conditions. The $492,500 award, granted on January 1, 2025, supports research at The Schepens Eye Research Institute, Inc. to generate iPSCs that express peptide-free or low-affinity peptide-loaded HLA-I molecules, protecting them from...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), will fund research to understand the genetic causes of inherited retinal degenerations (IRDs), a group of rare blinding diseases. The $1,369,782 award to the Massachusetts Eye and Ear Infirmary will support two key research aims: Developing a high-throughput splicing assay to identify rare coding and non-coding variants that lead to splicing defects and contribute to the...
This federal Project Grant award, provided by the National Eye Institute (CFDA 93.867 Vision Research), supports research at the Whitehead Institute for Biomedical Research to systematically identify and characterize novel oxidative protective genes that can prevent retinal pigment epithelium (RPE) degeneration and age-related macular degeneration (AMD). The $173,016 award, effective from Aug 1, 2025 to Jul 31, 2027, will fund a project focused on three primary aims: 1) elucidating the...
The National Eye Institute (NEI) awarded a $240,000 Project Grant (CFDA 93.867 - Vision Research) to Baylor College of Medicine to conduct research focused on "Characterization of the Nascent Retinal Proteome Regulating Hippo Signaling During Damage." The project aims to use cell type-specific metabolic labeling and purification techniques to identify the immediate molecular regulators of the Hippo signaling pathway in muller glial cells of the damaged mouse retina. This information is...